Document is current

Article History

Received: 6 September 2022

Revised: 9 January 2023

Accepted: 11 January 2023

First Online: 30 January 2023

Competing interests

: GG reports fees from EliLilly, Novartis and Gilead; FM reports fees from Novartis and Roche; FG reports fees from Gilead and Lilly; VG reports fees from Amgen, Exact Sciences, Gilead, GSK, EliLilly, Merck Serono, MSD, Novartis, Pfizer, Sanofi; MVD reports fees from AstraZeneca, Daiichi Sankyo, EliLilly, Exact Sciences, Gilead, MSD, Novartis, Pfizer, Seagen. WJ reports grants, personal fees and non-financial support from Astra Zeneca, personal fees and non-financial support from Eisai, personal fees and non-financial support from Novartis, personal fees and non-financial support from Roche, personal fees and non-financial support from Pfizer, personal fees and non-financial support from Eli Lilly, personal fees from MSD, personal fees from BMS, personal fees and non-financial support from Chugai, personal fees from Seagen, grants and personal fees from Daiichi Sankyo, outside the submitted work. The remaining authors declare no competing interests.

: The study was approved by the ethics committee of Istituto Oncologico Veneto and Montpellier Regional Cancer Institute and conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from participants, where necessary according to local regulation.

: Not applicable.